Table 3.
Proteins targeted by CAR T cell therapies in active clinical trials
| CAR target 1 | Active clinical trials | CAR target | Active clinical trials |
|---|---|---|---|
| CD33 | 1 | CD123 | 2 |
| CD133 | 1 | CD20 | 2 |
| CD138 | 1 | CD22 | 2 |
| CD171 | 1 | CEA | 2 |
| cMet | 1 | GPC3 | 2 |
| EphA2 | 1 | MUC1 | 2 |
| FAP | 1 | GD2 | 3 |
| IL13Ra2 | 1 | CD30 | 4 |
| LewisY | 1 | EGFRvIII | 4 |
| NKG2D ligands | 1 | HER2 | 4 |
| ROR1 | 1 | Mesothelin | 6 |
| BCMA | 2 | CD19 | 51 |
1
Shown is the protein targeted by CAR T cell therapies in active trials of solid and hematologic malignancies.
CD: cluster of differentiation; FAP: fibroblast activation protein; ROR: receptor tyrosine kinase-like orphan receptor; BCMA: B-cell maturation antigen; CEA: carcinoembryonic antigen; GPC3: glypican 3; HER2: human epidermal growth factor 2; MUC1: mucin 1; EGFRvIII: epidermal growth factor receptor variant III.